Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 214Lung Neoplasms 74Neoplasms 24Adenocarcinoma of Lung 16Neoplasm Metastasis 15Mesothelioma, Malignant 15Parkinson Disease 4, Autosomal Dominant Lewy Body 12Mesothelioma 12Carcinoma 11Head and Neck Neoplasms 10Breast Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6Ovarian Neoplasms 6Recurrence 5Pancreatic Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Lung Diseases 3Laryngeal Diseases 3Carcinoma, Small Cell 3Brain Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Thoracic Neoplasms 2Solitary Fibrous Tumor, Pleural 2

Interventions

Everolimus 16Octreotide 6pembrolizumab 5lanreotide 5Sunitinib 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3lenvatinib 3arginyllysine 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2pasireotide 2lutetium Lu 177 dotatate 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroendocrine Tumors × Pemetrexed × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡